The pace of discovery of new antiretroviral (ARV) drugs has slowed,although the efficacy and safety of once-daily fixed dose combinations have been extensively investigated.Several traditional ARV drugs remain in phase Ⅲ clinical trials.This review summarizes current information on ARV drugs in phase Ⅲ clinical trials and focuses on the development of ARV drugs in the next decade.